Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1970;43(Suppl):81–90.

Indoles

PMCID: PMC2427608  PMID: 20604381

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BELLEVILLE R. E., FRASER H. F., ISBELL H., LOGAN C. R., WIKLER A. Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry. 1956 Nov;76(5):468–478. [PubMed] [Google Scholar]
  2. COHEN S., DITMAN K. S. Prolonged adverse reactions to lysergic acid diethylamide. Arch Gen Psychiatry. 1963 May;8:475–480. doi: 10.1001/archpsyc.1963.01720110051006. [DOI] [PubMed] [Google Scholar]
  3. DELAY J., PICHOT P., LEMPERIERE T., NICOLAS-CHARLES P. Effets psychophysiologiques de la psilocybine. C R Hebd Seances Acad Sci. 1958 Oct 20;247(16):1235–1238. [PubMed] [Google Scholar]
  4. DELAY J., PICHOT P., LEMPERIERE T., NICOLAS-CHARLES P., QUETIN A. M. Les effets somatiques de la psilocybine. Ann Med Psychol (Paris) 1959 May;117(5):891–899. [PubMed] [Google Scholar]
  5. Ditman K. S., Tietz W., Prince B. S., Forgy E., Moss T. Harmful aspects of the LSD experience. J Nerv Ment Dis. 1967 Dec;145(6):464–474. doi: 10.1097/00005053-196712000-00004. [DOI] [PubMed] [Google Scholar]
  6. Dubanský B., Vyhnánková M. Pathologic laughter as manifestation of the psychotomimetic action of psilocybin. Act Nerv Super (Praha) 1965 Aug;7(3):307–307. [PubMed] [Google Scholar]
  7. Dubanský B., Vyhnánková M., Setlík L. Soucasný výskyt neurologických príznaků a zmeneného proprioceptivního vnímaní po psilocybinu u nemocných s organickým poskozením mozku. Cesk Neurol. 1968 Oct;31(6):394–399. [PubMed] [Google Scholar]
  8. Frosch W. A., Robbins E. S., Stern M. Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization. N Engl J Med. 1965 Dec 2;273(23):1235–1239. doi: 10.1056/NEJM196512022732302. [DOI] [PubMed] [Google Scholar]
  9. Gorodetzky C. W., Isbell H. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25. Psychopharmacologia. 1964 Sep 11;6(3):229–233. doi: 10.1007/BF00404013. [DOI] [PubMed] [Google Scholar]
  10. HOFMANN A., HEIM R., BRACK A., KOBEL H. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experientia. 1958 Mar 15;14(3):107–109. doi: 10.1007/BF02159243. [DOI] [PubMed] [Google Scholar]
  11. HOLLISTER L. E., PRUSMACK J. J., PAULSEN A., ROSENQUIST N. Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects. J Nerv Ment Dis. 1960 Nov;131:428–434. doi: 10.1097/00005053-196011000-00007. [DOI] [PubMed] [Google Scholar]
  12. ISBELL H. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia. 1959;1:29–38. doi: 10.1007/BF00408109. [DOI] [PubMed] [Google Scholar]
  13. ISBELL H., MINER E. J., LOGAN C. R. Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25). Psychopharmacologia. 1959;1:20–28. doi: 10.1007/BF00408108. [DOI] [PubMed] [Google Scholar]
  14. ISBELL H., WOLBACH A. B., WIKLER A., MINER E. J. Cross tolerance between LSD and psilocybin. Psychopharmacologia. 1961;2:147–159. doi: 10.1007/BF00407974. [DOI] [PubMed] [Google Scholar]
  15. Isbell H., Gorodetzky C. W. Effect of alkaloids of ololiuqui in man. Psychopharmacologia. 1966;8(5):331–339. doi: 10.1007/BF00453511. [DOI] [PubMed] [Google Scholar]
  16. PENNES H. H., HOCH P. H. Psychotomimetics, clinical and theoretical considerations: harmine, Win-2299 and nalline. Am J Psychiatry. 1957 Apr;113(10):887–892. doi: 10.1176/ajp.113.10.887. [DOI] [PubMed] [Google Scholar]
  17. ROSENBERG D. E., ISBELL H., MINER E. J., LOGAN C. R. THE EFFECT OF N,N-DIMETHYLTRYPTAMINE IN HUMAN SUBJECTS TOLERANT TO LYSERGIC ACID DIETHYLAMIDE. Psychopharmacologia. 1964 Feb 12;5:217–227. doi: 10.1007/BF00413244. [DOI] [PubMed] [Google Scholar]
  18. SCHNEIDER J. A., SIGG E. B. Neuropharmacological studies on ibogaine, an indole alkaloid with central-stimulant properties. Ann N Y Acad Sci. 1957 Mar 14;66(3):765–776. doi: 10.1111/j.1749-6632.1957.tb40765.x. [DOI] [PubMed] [Google Scholar]
  19. SOLMS H. Relationships between chemical structure and psychoses with the use of psychotoxic substances; comparative pharmacopsychiatric analysis: a new research method. J Clin Exp Psychopathol. 1956 Oct-Dec;17(4):429–433. [PubMed] [Google Scholar]
  20. SZARA S. Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism. Experientia. 1956 Nov 15;12(11):441–442. doi: 10.1007/BF02157378. [DOI] [PubMed] [Google Scholar]
  21. TURNER W. J., MERLIS S., CARL A. Concerning theories of indoles in schizophrenigenesis. Am J Psychiatry. 1955 Dec;112(6):466–467. doi: 10.1176/ajp.112.6.466-a. [DOI] [PubMed] [Google Scholar]
  22. WALASZEK E. J., CHAPMAN J. E. Bulbocapnine: an adrenergic and serotonin blocking agent. J Pharmacol Exp Ther. 1962 Sep;137:285–290. [PubMed] [Google Scholar]
  23. WOLBACH A. B., Jr, MINER E. J., ISBELL H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962;3:219–223. doi: 10.1007/BF00412109. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES